Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 12/20 | 0.52 |
| ▸ | INSR | P06213 | 9/20 | 0.52 |
| ▸ | IGF1R | P08069 | 9/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19921137 | 0.94 | ALK (0.62) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL19921199 | 0.92 | ALK (0.49) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL19921198 | 0.89 | ALK (0.51) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL19929891 | 0.86 | EGFR (0.41) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL19921194 | 0.86 | ALK (0.59) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL19921120 | 0.86 | ALK (0.70) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL19921124 | 0.86 | ALK (0.56) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL20546932 | 0.86 | ALK (0.65) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL21099428 | 0.85 | ALK (0.60) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL19921135 | 0.85 | CCNK (0.50) | ALKEGFRMAP3K7PTK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290420-B1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | UNIV XIAMEN (CN) | 2020-12-09 | — | — | EP | claimed |
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2018-11-01 | — | — | US | claimed |
| EP-3290420-A1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Xiamen University (CN) | 2018-03-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | TPMT, DHPS, TYMP | ALK 1505/4885INSR 3191/4885IGF1R 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.